Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer.

[1]  J. Pijoan,et al.  Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  A. Kishan,et al.  Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. , 2017, Brachytherapy.

[3]  W. J. Morris,et al.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.

[4]  W. J. Morris,et al.  ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. , 2017, International journal of radiation oncology, biology, physics.

[5]  J Alfred Witjes,et al.  Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. , 2016, European urology.

[6]  A. Padhani,et al.  Finding Minimal Extraprostatic Disease: Who Cares? , 2016, European urology.

[7]  J. Crook,et al.  Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  M. Recio,et al.  Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy , 2015, SpringerPlus.

[9]  A. Kishan,et al.  Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. , 2015, Practical radiation oncology.

[10]  N. Cho,et al.  Prediction of Micrometastasis (< 1 cm) to Pelvic Lymph Nodes in Prostate Cancer: Role of Preoperative MRI. , 2015, AJR. American journal of roentgenology.

[11]  M. Milette,et al.  Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion. , 2014, Brachytherapy.

[12]  Jeong Kon Kim,et al.  Predictors of unfavorable disease after radical prostatectomy in patients at low risk by D'Amico criteria: role of multiparametric magnetic resonance imaging. , 2014, The Journal of urology.

[13]  Shyam Natarajan,et al.  The role of magnetic resonance imaging in delineating clinically significant prostate cancer. , 2014, Urology.

[14]  F. Montorsi,et al.  Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  A. D'Amico,et al.  Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[16]  S. Hazell,et al.  Margin status after laparoscopic radical prostatectomy and the index lesion: implications for preoperative evaluation of tumor focality in prostate cancer. , 2012, Journal of endourology.

[17]  F. Beuvon,et al.  Endorectal 3D T2-weighted 1mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: should we reconsider the indirects signs of extracapsular extension according to the D'Amico tumor risk criteria? , 2012, European journal of radiology.

[18]  R. Hoffman,et al.  Clinical practice. Screening for prostate cancer. , 2011, The New England journal of medicine.

[19]  A. Partin,et al.  A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy. , 2011, The Journal of urology.

[20]  F. Beuvon,et al.  Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer , 2011, Prostate Cancer and Prostatic Diseases.

[21]  Andrew J Vickers,et al.  Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Bruno Speleers,et al.  Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. , 2008, International journal of radiation oncology, biology, physics.

[23]  Shugo Suzuki,et al.  Pitfalls with MRI Evaluation of Prostate Cancer Detection , 2006, Urologia Internationalis.

[24]  Murray Krahn,et al.  Prostate Cancers Scored as Gleason 6 on Prostate Biopsy are Frequently Gleason 7 Tumors at Radical Prostatectomy: Implication on Outcome , 2006 .

[25]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[26]  R. Valicenti,et al.  Combining external beam radiotherapy with prostate brachytherapy: issues and rationale. , 2004, Urology.

[27]  Christopher R King,et al.  Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. , 2004, International journal of radiation oncology, biology, physics.

[28]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .